Vol. 42 (2): 407-408, May – June, 2016
Bucal Mucosa Graft in Long Anterior Urethral Stenosis – Dorsal or Ventral?
The May-June 2016 issue of the International Braz J Urol presents original contri¬butions with a lot of interesting papers in different fields: Urinary Incontinence, Urethral Stricture, Bladder Cancer, Pelvic-Ureteric Junction Stenosis, BPH, Prostate Cancer, Renal stones, Uroginecology, Pediatric Urology and basic research. The papers come from many different countries such as Brazil, USA, Turkey, Italy, Austria, Australia, Israel, Netherlan¬ds, India, Mexico, China, Saudi Arabia, United Kingdon, Korea and France, and as usual the editor ́s comment highlights some papers. We decided to comment 2 papers about a very usual topic in urologic practice: The Urethral Stricture.
Doctor Prabha and collegues from India performed on page 564 an interesting study about the single stage dorsolateral onlay buccal mucosal urethroplasty for long an-terior urethral strictures. The authors studied 20 patients with urethral strictures: Lichen sclerosis in 12 cases (60%), Instrumentation in 5 cases (25%), and unknown in 3 cases (15%). Strictures were approached through a perineal skin incision and penis was invagi-nated into it to access the entire urethra. All the grafts were placed dorsolaterally, preser¬ving the bulbospongiosus muscle, central tendon of perineum and one-sided attachement of corpus spongiosum. The mean stricture length was 8.5cm (range 4 to 12cm) and the overall success rate was 85%. There were 3 failures (meatal stenosis in 1, proximal stric¬ture in 1 and whole length recurrent stricture in 1). Other complications included wound infection, urethrocutaneous fistula, brownish...
Vol. 42 (2): 409-412, May – June, 2016
EDITORIAL IN THIS ISSUE
From robot to molecule, the behavior
In general Urology, forty per cent of ambulatory consultations are intended to prostate care, as well as consultation in geriatrics and clinical medicine. It is observed statistically that one in every six men over 50 years will present prostate cancer (PCa) throughout live (1). It is the second most prevalent cancer in men, following skin cancer, with an estimate of 61,200 new cases in 2016, according to INCA (National Cancer Institute of Brazil).
Recent scientific knowledge and incorporation of new technologies lead to higher interaction with molecular epidemiology and cancer genetics. They explain why some patients will present slower progression of the disease, allowing for active surveillance, and also the use of newer and lesser aggressive treatments with higher survival with good quality of life. Epigenetic and genetic alterations provide a mosaic of tumor clones that determine respectively heterogeneous histologically phenotypic tumors, with corresponding indolent clinical symptoms or a more aggressive progression (2).
Currently, renal tumors are efficiently treated due to precision and richer details provided by modern image technologies. We are able to detect in daily practice the aggressiveness of the lesion according to dimension, morphology, tissue density, perfusion and anatomic relations, allowing the choice of the most adequate treatment. Actually, current image exams reflect more accurately the tumor microenvironment. In the same way, evaluation of prostate gland by multiparametric magnetic resonance provides data related to morphology, perfusion, diffusion and spectroscopy, that matches more...